Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-Ab™
Target-Humanized Mouse Models (HUGO-GT™)
Target-Humanized Mouse Models (CDS)
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Custom Model Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Preclinical Solutions
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic
Obesity
MASH & MASLD
Cardiovascular
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Retinal-related diseases
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Systemic Lupus Erythematosus
Drug Classification
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
iCyagen
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Company Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeBlogs & InsightsAlzheimer's Disease Mouse Models: Transgenic Mice and Knock-in Rodents
Neuroscience

Alzheimer's Disease Mouse Models: Transgenic Mice and Knock-in Rodents

Cyagen Technical Content Team | Updated on November 18, 2026
Empower Your Alzheimer's Drug Discovery Pipeline
Explore Cyagen's Alzheimer's disease CRO services to pair our humanized APP mice with behavioral and pathology assessments tailored to your preclinical study.
Empower Your Alzheimer's Drug Discovery Pipeline
Contents
Alzheimer's Disease Mouse Models: Transgenic Mice and Knock-in Rodents
01. Alzheimer's Disease Mouse Models: Transgenic Mice and Knock-in Rodents 02. Overview of Transgenic Mouse Models for Alzheimer's Disease 03. Knock-in Rat Models of Alzheimer's Disease 04. Cyagen Humanized Mouse Models for AD Research 05. Practical Considerations for Choosing a Mouse Model of Alzheimer's Disease 06. Neuroscience Models and CRO Services 07. Reference

Alzheimer's Disease Mouse Models: Transgenic Mice and Knock-in Rodents

Memory loss is the most familiar sign of Alzheimer’s disease (AD), but the underlying pathology begins years before symptoms become apparent. By the time clinical symptoms emerge, amyloid-β (Aβ) accumulation has often been ongoing for years, while tau pathology and neurodegeneration may already be underway. FDA-approved anti-amyloid therapies, including lecanemab and donanemab, have demonstrated the ability to slow clinical decline in patients with early symptomatic AD and confirmed amyloid pathology. For preclinical research, the question is not simply whether an animal model develops AD-like pathology, but which pathological features emerge, when they appear, and how consistently they can be measured.

In our earlier Alzheimer's disease research article, we surveyed three approaches to modeling AD-related pathology: aging, Aβ exposure, and genetic modification. Of the three, genetic modification offers a more predictable way to model disease onset and progression, which is why it underpins much of today's work on alzheimer's disease models work today. Here we review commonly used genetically engineered AD models, followed by Cyagen's humanized APP models and related neuroscience research capabilities:

  • The App NL-G-F knock-in rat
  • Humanized App knock-in mice
  • Other neurological disease models
  • Neuroscience CRO services

Overview of Transgenic Mouse Models for Alzheimer's Disease

Many widely used transgenic mouse models of Alzheimer's disease express variants of amyloid precursor protein (APP) associated with familial AD. Four commonly studied lines are APP/PS1, Tg2576, 3xTg-AD, and 5xFAD [1].

APP/PS1 model

The APPswe/PSEN1dE9 model (line 85) carries a mouse-human chimeric APP695 transgene with the Swedish mutation (K670_M671delinsNL) and a human PSEN1 transgene lacking exon 9. The mouse prion protein promoter drives both transgenes. The two transgenes are co-integrated at a single locus and are therefore inherited together.

Amyloid plaques accumulate with age in the cortex and hippocampus [2], and plaque burden varies by brain region [3]. In some cohorts, spatial memory deficits have been detected in the Morris water maze by 6 months of age [2].

Tg2576 model

Tg2576 mice express human APP695 carrying the Swedish double mutation (K670_M671delinsNL) under the hamster prion protein promoter. This mouse model exhibits age-related increases in cerebral Aβ levels and plaque burden.

Dendritic spine loss has been reported in the hippocampal CA1 region at 4.5 months of age [4]. Some studies have detected deficits in contextual fear conditioning or working memory before 6 months. Spatial memory deficits have been reported at 9-10 months [5], and substantial cerebral Aβ plaque deposition at 11-13 months [6].

3xTg-AD model

The 3xTg-AD model carries human APP Swedish and MAPT P301L transgenes together with an M146V knock-in mutation in the endogenous mouse Psen1 gene. P301L is associated with frontotemporal dementia and is used here to model tau aggregation. Although the model develops both amyloid and tau pathology, its tau component is driven by a familial frontotemporal dementia-associated MAPT mutation rather than the full range of tau changes observed in sporadic AD.

In the original colony, extracellular Aβ deposits appeared in the cortex by 6 months and became more widespread by 12 months, when neurofibrillary tangles were also evident. Early studies reported learning and memory deficits at 3-6 months [7]. In a follow-up study of 3xTg-AD mice, plaques appeared later than originally reported and were more prominent in females than in males [8]. This finding helps put a common question in context: Why is it better to have female mouse models for Alzheimer’s disease? In this colony, the greater plaque burden observed in females may favor their use when amyloid deposition is the primary endpoint. Both sex and colony history should guide the choice of age for assessment.

5xFAD model

The 5xFAD model expresses human APP carrying the Swedish (K670_M671delinsNL), Florida (I716V), and London (V717I) variants, together with human PSEN1 carrying M146L and L286V. The mouse Thy1 promoter drives both transgenes. Cerebral Aβ deposition and plaque burden increase with age.

Amyloid plaques appear as early as 2 months in the subiculum and deep cortical layers. With age, deposits have also been reported in other regions, including the thalamus and spinal cord [9-11]. Learning and memory deficits have been reported at 6-12 months [5]. Some cohorts show reduced spontaneous alternation in a Y-maze or cross-maze as early as 3-6 months.The model is particularly useful for studying aggressive amyloid pathology and associated neuroinflammation, but it does not reproduce the full spectrum of tau pathology seen in human AD.

Figure 1. Early transgenic mouse models used in Alzheimer’s disease research [12].
Figure 1. Early transgenic mouse models used in Alzheimer’s disease research [12].

Knock-in Rat Models of Alzheimer's Disease

Many APP-based mouse models develop Aβ plaques but lack mature neurofibrillary tangles. The rat offers another way to examine how amyloid deposition relates to changes in endogenous tau. Adult rats express both three-repeat (3R) and four-repeat (4R) tau isoforms, as humans do, although in different proportions. Their larger body size also facilitates repeated sampling of cerebrospinal fluid.

App NL-G-F Knock-in rat model

In 2021, Pang and colleagues reported the App NL-G-F knock-in rat [13]. It carries a humanized Aβ sequence and three familial AD mutations (Swedish, Iberian, and Arctic) at the endogenous App locus. Levels of full-length APP and the measured C-terminal fragments were comparable to those in wild-type samples. The researchers observed Aβ aggregation and changes in endogenous tau without introducing a mutant human MAPT transgene.

In homozygous rats, the researchers detected a weak plaque signal at 1 month. Aβ deposition increased with age and progressed more rapidly in females in the brain regions examined. The authors also reported neuronal loss in the hippocampus and cortex and enlargement of the lateral ventricles. At 12 months, homozygous knock-in rats had approximately 30% fewer NeuN-positive neurons in the hippocampal sections examined than wild-type controls, and their brain weight was 9% lower. These differences increased to approximately 50% and 16%, respectively, at 22 months. The rats performed worse than controls in the Morris water maze at 5-6 months and on a paired-associate learning task at 7-8 months. The researchers also detected increased phosphorylation at selected tau epitopes by 6 months and staining consistent with tau aggregation at 12 months.

Figure 2. Timing of reported pathological changes in App NL-G-F rats [12]
Figure 2. Timing of reported pathological changes in App NL-G-F rats [12]

Cyagen Humanized Mouse Models for AD Research

The App NL-G-F rat shows what an endogenous knock-in offers: human mutations expressed from the native App locus rather than from a randomly integrated transgene. The same design can be applied in mice, which additionally bring a long record of published behavioral protocols and a large catalog of other genetically modified lines available for crossing. Cyagen’s three humanized App knock-in mouse models follow this design, placing familial APP mutations at the mouse App locus on a C57BL/6 background.

hAPP-NL-F Mouse (Cat. C002124)

The mouse App sequence from downstream of the signal peptide coding region into intron 1 is replaced with a human APP coding cassette carrying the Swedish (K670N/M671L) and Iberian (I716F) mutations, so the mouse signal peptide is retained and the humanized sequence remains under the control of the endogenous App locus. The two mutations act at different cleavage sites. The Swedish mutation sits at the β-secretase site and increases total Aβ production, while the Iberian mutation sits near the γ-secretase site and raises the Aβ42 to Aβ40 ratio in favor of the more aggregation-prone Aβ42 peptide. This is the two-mutation member of the set; the two lines below carry additional mutations.

Explore this model ->

hAPP-NL-G-F Mouse (Cat. C002125)

This line uses the same humanization strategy as C002124 and adds a third mutation, Arctic (E693G), inside the Aβ sequence itself, where it promotes Aβ protofibril formation. Because the two lines are otherwise identical in construct design and genetic background, comparing age- and sex-matched cohorts isolates the contribution of the Arctic substitution.

Explore this model ->

huAPP-Aβ-NL-G-F-I Mouse (Cat. C002033)

This line humanizes a different part of the gene. The mouse App region from upstream of exon 16 to downstream of exon 17 is replaced with the corresponding human sequence, so the Aβ domain and its flanking cleavage sites are human while the remainder of APP stays murine. It carries four familial mutations: Swedish, Arctic, Iberian, and London (V717I), the last of which is also associated with an increased Aβ42 to Aβ40 ratio. Together with C002124 and C002125, it gives a choice between two humanization strategies that differ in how much of the APP coding sequence is human.

Explore this model ->

All three strains are available as live mice for AD and cerebral amyloid angiopathy research. For studies screening APP-targeted therapeutics, model selection depends on whether the line contains the target sequence and shows a measurable change in the intended endpoint over the study period.

Practical Considerations for Choosing a Mouse Model of Alzheimer's Disease

No single model answers every question. When choosing among Alzheimer's disease mouse models, first consider whether a mouse is the right species for your study.

If the study calls for repeated cerebrospinal fluid sampling, or depends on endogenous 3R and 4R tau expression, the App NL-G-F rat may offer practical advantages over conventional mouse models.

Then decide how much of APP needs to be human. C002124 and C002125 carry a human APP coding cassette downstream of the mouse signal peptide sequence, whereas C002033 carries human genomic sequence spanning exons 16 and 17 only. Check the region your agent or detection assay recognizes against the construct design of each line.

Next, consider whether a second genetic factor is involved. If the mechanism under study also implicates tau, APOE4, TREM2, or receptor-mediated transport across the blood-brain barrier, a cross with the corresponding humanized line may be more informative than either line on its own.

Finally, match the behavioral readout to the function in question. The Morris water maze, for example, measures spatial learning and memory, and is appropriate only if that is the function the intervention is expected to affect. Published data from the same strain, age, sex, and genetic background should guide the expected testing window and phenotype variability. Cohort size should then be determined through an appropriate prospective power analysis. Behavioral outcomes should also be interpreted alongside relevant motor, visual, and general activity controls to minimize non-cognitive confounding factors.

Neuroscience Models and CRO Services

The same gene-editing platform extends beyond Alzheimer's disease modeling. Cyagen’s neurological disease models cover Parkinson’s disease (Snca, Lrrk2), amyotrophic lateral sclerosis (Sod1, Fus, Tardbp), Huntington’s disease (Htt), spinal muscular atrophy (Smn1, human SMN2 knock-in), frontotemporal dementia (Mapt), spinocerebellar ataxia (Atxn3), and models used to study behaviors relevant to anxiety, depression, and autism. Depending on the research target and project requirements, model development may involve selected catalog strains, custom knockout, conditional knockout, knock-in or humanized models, as well as induced models. Behavioral paradigms relevant to anxiety-, depression-, and autism-related research can also support neuroscience studies.

Selecting a strain is only part of the work. Through its AD CRO services platform, Cyagen runs studies on catalog or investigator-provided lines, with behavioral assessment covering the Morris water maze, Y-maze, novel object recognition, open field, elevated plus maze, rotarod, and grip strength tests. These can be combined with stereotactic, intracerebroventricular, or systemic dosing and with histological and molecular readouts, including immunohistochemistry, immunofluorescence, plaque imaging, Western blotting, ELISA, and qPCR.

Reference

[1] Kosel F, Pelley JMS, Franklin TB. Behavioural and psychological symptoms of dementia in mouse models of Alzheimer's disease-related pathology. Neurosci Biobehav Rev. 2020 May;112:634-647.

[2] Minkeviciene R, Ihalainen J, Malm T, Matilainen O, Keksa-Goldsteine V, Goldsteins G, Iivonen H, Leguit N, Glennon J, Koistinaho J, Banerjee P, Tanila H. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem. 2008 May;105(3):584-94.

[3] Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fülöp L, Penke B, Zilberter Y, Harkany T, Pitkänen A, Tanila H. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009 Mar 18;29(11):3453-62.

[4] Lanz TA, Carter DB, Merchant KM. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis. 2003 Aug;13(3):246-53.

[5] Spires-Jones T, Knafo S. Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast. 2012;2012:319836.

[6] Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997 Sep;56(9):965-73.

[7] Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005 Mar 3;45(5):675-88.

[8] Yang JT, Wang ZJ, Cai HY, Yuan L, Hu MM, Wu MN, Qi JS. Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer's Disease. Neurosci Bull. 2018 Oct;34(5):736-746. doi: 10.1007/s12264-018-0268-9. Epub 2018 Aug 11.

[9] Richard BC, Kurdakova A, Baches S, Bayer TA, Weggen S, Wirths O. Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2015;45(4):1223-36.

[10] Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging. 2012 Jan;33(1):196.e29-40.

[11] Giannoni P, Arango-Lievano M, Neves ID, Rousset MC, Baranger K, Rivera S, Jeanneteau F, Claeysen S, Marchi N. Cerebrovascular pathology during the progression of experimental Alzheimer's disease. Neurobiol Dis. 2016 Apr;88:107-17. Epub 2016 Jan 8.

[12] Götz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008 Jul;9(7):532-44.

[13] Pang K, Jiang R, Zhang W, Yang Z, Li LL, Shimozawa M, Tambaro S, Mayer J, Zhang B, Li M, Wang J, Liu H, Yang A, Chen X, Liu J, Winblad B, Han H, Jiang T, Wang W, Nilsson P, Guo W, Lu B. An App knock-in rat model for Alzheimer's disease exhibiting Aβ and tau pathologies, neuronal death and cognitive impairments. Cell Res. 2022 Feb;32(2):157-175. Epub 2021 Nov 17.

Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
The Brain-Body Axis at SfN 2026: GLP-1, Addiction, and Alzheimer's Research
What Is a Fully Human Antibody Mouse Model, and How Does It Work?
PepGen's DM1 Data: Splicing Correction and the Preclinical Questions Ahead
AMT-130 and HTT-Lowering Therapies: Lessons from Preclinical Huntington's Disease Models
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCompany OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2026 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research